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ABSTRACT
On 4–5 March, 2016 the next symposium of the European Society for Medical Oncology (ESMO) about “Signalling 
pathways in cancer” was held in Sitges, Spain. The topics of the lectures were focused this year on mechanisms 
of action, resistance, new drugs, and the development of new therapies targeting human epidermal growth factor 
(HER) family receptors. During two days of symposium participants had an opportunity to familiarise themselves 
with the results of current research relevant to the main topic. This summary discusses selected topics presented 
during the symposium.
Key words: symposium, ESMO, EGFR, HER receptor, resistance, trastuzumab, pertuzumab
Oncol Clin Pract 2016; 12, 2: 63–66
Oncology in Clinical Practice
2016, Vol. 12, No. 2, 63–66
Translation: dr n. med. Dariusz Stencel
Copyright © 2016 Via Medica
ISSN 2450–1654
Introduction
On 4–5 March, 2016 the next symposium of the 
European Society for Medical Oncology (ESMO) about 
“Signalling pathways in cancer” was held in Sitges, Spain, 
and its main topic concentrated on signalling pathway 
connected to HER/EGFR family receptors. This meet-
ing was organised in collaboration with the European 
Association for Cancer Research (EACR) and the 
co-chairman was Professor Joseph Tabernero from 
Spain and Professor Clare Isacke from UK.
The meeting started with the presentation of mech-
anisms of action of different targeted therapies. The 
next topic included the role of circulating biomark-
ers, cancer DNA, and interactions between tumour 
microenvironment and stroma. Due to the speaker’s 
absence the participants had no opportunity to listen 
to the lecture about mechanisms of immunological 
regulation in the microenvironment between tumour 
and host. Furthermore, the mechanisms of resistance 
to drugs targeting HER family receptors were dis-
cussed based on some therapies used in patients with 
colorectal cancer (CRC), lung cancer (LC), and breast 
cancer (BC). Additionally, professor Richard Marais 
presented previous experience regarding the resistance 
to drugs targeted other signalling pathways in patients 
with melanoma.
During the next day molecular features of breast 
cancer, colorectal cancer, lung cancer, and gastric cancer 
were discussed together with a detailed presentation of 
the role of anti-HER drugs in patients with those malig-
nancies. During the closing session the speakers focused 
on new possibilities of development of precise medicine 
and some examples of its use in daily clinical practice.
The summary discusses the selected, main topics 
presented during the symposium.
Circulating biomarkers and circulating 
tumour DNA
Circulating tumour cells (CTCs) are released from 
the primary tumour and circulate in the bloodstream. 
It is believed that CTCs are important contributors in 
producing of distant metastases and possibility of their 
usefulness in clinical practice was already proven [1].
Cancer cells release their DNA fragments to the 
bloodstream, which are called circulating tumour DNA 
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(ctDNA) [1]. Usually ctDNA levels in blood increase 
with the tumour size. It is believed that ctDNA measure-
ment could allow in the future the assessment of cancer 
disease stage and monitoring of treatment efficacy as 
well as disease progression [1].
Mechanisms of resistance
Lung cancer
The reasons of resistance against the drugs targeting 
epidermal growth factor receptor (EGFR) in patients 
with lung cancer includes the presence of T790M muta-
tion of EGFR gene (50–60%), mutation of HER2 gene 
(8–12%), amplification of MET (5–20%), or conversion 
into small cell lung cancer (SCLC) (< 5%) [1].
Professor Fortunato Ciardiello quoted during his 
lecture the results of Hata at al. study. Although the 
mechanisms of acquired resistance to EGFR inhibitors 
in patients with non-small cell lung cancer (NSCLC) 
were identified, there is still sparse information about 
evolution of resistant clones during therapy. Authors 
noted that acquired resistance due to EGFR T790M 
mutation could be a result of either the selection of 
previously existing EGFR T790M-positive clones or 
genetic evolution of previously EGFR T790M-negative 
cells [2]. Those cells had reduced apoptotic response to 
third generation EGFR inhibitors regardless of mecha-
nism of induction. Treatment with navitoclax restored 
a sensitivity, which was already confirmed in the cells 
directly derived from patients with cancers resistant to 
EGFR inhibitors [2].
Two new clinical trials confirmed that mechanisms of 
acquired resistance to targeted therapy in NSCLC patients 
did not necessarily have to be connected with resistant 
subclones present from the beginning of the disease. 
Some cancers could show the potency to develop the 
mechanisms of resistance to targeted therapy after previ-
ous achieving response to the mentioned treatment [1–3]. 
During the next part of the lecture the registered 
indications to osimertinib treatment were discussed. In 
November 2015 the U.S. Food and Drug Administration 
(FDA) registered osimertinib for the treatment of adult 
patients with locally advanced or metastatic non-small 
cell lung cancer with T790M mutation in EGFR gene 
[4, 5]. At the same time the FDA approved cobas® 
EGFR Mutation Test V2, adding T790M mutation to 
clinically important mutations, identified up to now 
by original cobas® EGFR Mutation Test (V1) [4]. In 
December, 2015 the Committee for Medicinal Products 
for Human Use (CHMP) of the European Medicines 
Agency (EMA) issued a positive opinion regarding 
conditional marketing authorisation of osimertinib in 
the above-mentioned indications [6].
Breast cancer
In the part dedicated to anti-HER2 therapy in 
patients with BC, a few possible mechanisms were 
presented, among them the development of cancer 
adaptation during treatment caused by increased 
expression of HER2 receptor [1]. Other mechanisms 
include structural changes of HER2 protein, alternative 
increasing of activity of other receptors with tyrosine 
kinase domain, like insulin-like growth factor recep-
tor (IGFR), or changes within intracellular signalling 
pathways HER2-dependent, particularly involved in 
phosphatase and tensin homolog (PTEN) activity and 
PI3K/Akt pathway [7].
The potential possibility of reversing resistance to 
anti-HER2 therapy by activation of the immune system 
(e.g. combination of anti-HER2 and anti-PD1 drugs) 
was also presented [1].
Currently there is no known biomarker allowing 
prediction of the resistance to anti-HER2 therapy.
In summary, solutions were suggested, aimed at 
overcoming resistance to anti-HER2 therapy in patients 
with BC by administration of double HER2 blockade, 
inhibiting PI3K/mTOR pathway, immunomodulation, 
or blocking of oestrogen receptor in patients with 
tumour indicating its expression and overexpressing 
HER2 receptors [1].
Molecular features
Regarding BC, the participants were familiarised 
with already known data and additionally with the role 
of PIK3CA mutations. They are the most frequently 
observed in tumours indicating expression of oestro-
gen receptors and are associated with other factors of 
good prognosis [8]. PIK3CA mutations can coexist with 
HER2 amplification and PTEN protein loss [8]. It is 
acknowledged that PIK3CA mutations are potentially 
a good prognostic factor, however, during trastuzum-
ab-based therapy, the presence of PIK3CA mutations 
may be connected with worse tumour response as well 
as an uncertain influence on disease-free survival and 
overall survival [1, 8]. Recent results of clinical trials 
show that the presence of PIK3CA mutation does 
not guarantee a spectacular response to treatment 
with PI3K inhibitors [8]. Currently there are no data 
supporting the recommendation of routine PIK3CA 
genotyping [8].
There were four consensus molecular subtypes 
(CMSs) of CRC, distinguished based on the publica-
tion of Guinney et al.: CMS1 (microsatellite instability 
immune, 14%), hypermutated, microsatellite unstable 
and strong immune activation; CMS2 (canonical, 37%), 
epithelial, marked WNT and MYC signaling activa-
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tion; CMS3 (metabolic, 13%), epithelial and evident 
metabolic dysregulation; and CMS4 (mesenchymal, 
23%), prominent transforming growth factor–b acti-
vation, stromal invasion and angiogenesis [9]. It was 
highlighted during the symposium, that not only in 
CMS1 subtype (immuno-activated) immune system 
cells play some role [1]. In other subtypes immune 
system is acting in different way: immuno-ignorant in 
CMS2 and CMS3 subtypes and immuno-tolerant in 
CMS4 subtype [1].
Therapies targeting HER family 
receptors in selected malignancies
The results of the HERACLES trial were quoted 
several times during the symposium. Eligible patients 
include those with metastatic CRC with disease pro-
gression after use of derivatives of fluoropyrimidines, 
oxaliplatin, irinotecan, bevacizumab, and cetuximab 
or panitumumab, and with HER2 overexpression 
in tumour cells [10]. Patients received lapatinib in 
combination with trastuzumab weekly in standard 
doses. Response to the treatment was evaluated every 
eight weeks. The primary endpoint was objective re-
sponse (OR) with use of Response Evaluation Criteria 
in Solid Tumours (RECIST) criteria, version 1.1 (v 1.1). 
The median age of the patients was 61 years. ORs were 
indicated in 6/18 patients (one complete response, four 
partial responses, one unconfirmed partial response; 
ORR = 33.3%, 95% CI 0.16–0.56) [10]. Additionally 
four patients achieved disease stabilisation lasting over 
four months. The treatment was well tolerated. Grade 
2 diarrhoea, fatigue, and skin toxicities (grade 3 in one 
patient) were noted. The authors highlighted that the 
results of that study confirm the activity of combination 
treatment with lapatinib together with trastuzumab in 
patients with CRC who met the inclusion criteria [10].
One of the most highly anticipated lectures was the 
presentation by Dr. Javier Cortés about the current 
possibilities of anti-HER2 therapy and its develop-
ment in BC patients. Due to spectacular results of the 
CLEOPATRA (Clinical Evaluation of Pertuzumab 
and Trastuzumab) study, its results could not be missed 
during this year’s symposium. CLEOPATRA is a mul-
ticentre, randomised, double-blinded, controlled 
phase III study, evaluating the efficacy and safety of 
systemic therapy with pertuzumab. Eligible patients 
were patients with, locally recurrent, unresectable, or 
metastatic HER2-positive breast cancer, previously 
untreated with chemotherapy or biological drugs due to 
metastatic disease [11]. The patients were randomised 
into groups receiving either placebo with trastuzumab 
and docetaxel or pertuzumab with trastuzumab and 
docetaxel. Patients were allowed to receive previously 
neoadjuvant or adjuvant chemotherapy with trastu-
zumab; however, it should be at least one year since ces-
sation of the mentioned treatment. The primary end-
point of the study was progression-free survival (PFS), 
assessed by an independent review facility. Secondary 
endpoints included: overall survival (OS), PFS assessed 
by investigators, objective response rate (ORR), and 
safety. The independent review facility revealed signifi-
cant prolongation of median PFS by 6.1 months (up 
to 18.5 months) in the pertuzumab-treated group (HR 
0.62; 95% CI 0.51–0.75; p < 0.001) [11]. After an addi-
tional year of follow-up the median OS was 37.6 months 
in the control group, but it was not reached in the group 
treated with pertuzumab. Medians PFS assessed by 
the investigators were 12.4 months and 18.7 months 
in favour of the group receiving pertuzumab [12]. In 
final analysis, performed in 2015, medians OS were 
56.5 months and 40.8 months in the groups receiving 
pertuzumab and placebo, respectively [13]. Thus, there 
was an increase in the OS median by 15.7 months in 
the group treated with pertuzumab [13].
Clinical trials with new compounds targeting 
HER2 in patients with BC were also presented 
(examples include margetuximab [monoclonal an-
tibody against HER2] or MM-302) [14, 15]. MM- 
-302 compound (HER2-targeted liposomal doxoru-
bicin hydrochloride) is the drug targeting domain I of 
HER2 receptor [1, 14]. Taking into consideration its 
target point, which is different than trastuzumab and 
pertuzumab, it could be used in the future after dis-
ease progression in patients in whom those drugs were 
already administered, or it could be an alternative in 
combined treatment of double blockade of HER2 re-
ceptor. This matter demands further clinical trials [1]. 
Summary
In this annual ESMO symposium dedicated to the 
role of signalling pathways in cancers it was very impor-
tant to present the current results of clinical trials with 
therapies targeting HER family receptors because the 
class of anti-HER drugs is being continuously devel-
oped. International sharing of experience, knowledge, 
and collaboration are essential factors contributing to 
the further development of anti-cancer drugs.
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